Safety and Effectiveness of Half-Dose Recombinant Staphylokinase Before Primary PCI for ST-Elevation Myocardial Infarction A Multicenter Randomized Placebo-Controlled Trial
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-10-30
2260
Participants Needed
61
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of a half-dose bolus of recombinant staphylokinase r-SAK given before primary percutaneous coronary intervention PCI in patients with acute ST-segment elevation myocardial infarction STEMI. This phase 4, multi-center, randomized, double-blind, placebo-controlled trial aims to determine whether adding r-SAK immediately before PCI improves outcomes compared to placebo within 120 minutes of the procedure. The study is motivated by the need to improve early reperfusion and reduce heart damage in STEMI patients.
Participants are randomly assigned to receive either a single intravenous bolus of 5 mg r-SAK over 3 minutes or a placebo injection within 10 minutes after STEMI diagnosis and before PCI. The trial compares these two groups to assess the impact on major adverse cardiovascular events MACE within 90 days. The study also monitors other heart and brain event outcomes, heart function measures, and blood flow grades before and after PCI.
During the study, participants undergo assessments including cardiac magnetic resonance imaging, echocardiograms, and blood tests for heart-related biomarkers at specified days up to 360 days after treatment. Researchers observe the occurrence of cardiovascular events, measure heart function, and monitor safety outcomes throughout the trial period. Participants are followed to evaluate both short-term and longer-term effects of the treatment compared to placebo.
CONDITIONS
Brief Title
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
Research Team
C
Chunjian Li, PHD
C
Chen Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 to 75 years and weight at least 45 kg
Diagnosed with STEMI with ischemic chest pain lasting 30 minutes or more
ECG showing ST-segment elevation in specified leads
Time from chest pain onset to randomization is 12 hours or less
Primary PCI expected to be performed between 30 and 120 minutes after diagnosis
You will not qualify if you...
Cardiogenic shock
Active bleeding or high risk of bleeding, including recent serious eye or gastrointestinal bleeding
Ischemic stroke or transient ischemic attack within past 6 months
History of hemorrhagic stroke
Known intracranial aneurysm
Severe trauma, surgery, or head injury within 1 month
Suspected aortic dissection or infective endocarditis
Recent puncture with difficult bleeding control within 1 month
Current use of anticoagulants
Anemia with hemoglobin less than 10 g/dL
Thrombocytopenia with platelet count below 100 x 10^9/L
Poorly controlled high blood pressure (180/110 mmHg or higher)
Severe liver or kidney impairment
Known allergy to r-SAK
Pregnancy, breastfeeding, or planning pregnancy
History of chronic total occlusion, prior myocardial infarction, or coronary artery bypass grafting
Use of antiplatelet drugs other than aspirin or ticagrelor after symptom onset
Other conditions making participation unsuitable as judged by investigators
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Within 12 hours of symptom onset
Participants receive either a half-dose bolus of r-SAK or a placebo injection before undergoing primary PCI.
Single treatment visit with PCI procedure
Follow-up
Duration - Up to 360 days
Participants are monitored for major adverse cardiovascular events and heart function through imaging, blood tests, and clinical visits up to 360 days after treatment.
Scheduled visits for assessments at days 5, 7, 90, and 360
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluation of Coronary Microvascular Function Using Continuous Saline Thermodilution in Patients With ST-Elevation Myocardial Infarction Undergoing Primary PCI
Using Cell Free DNA to Detect Heart Inflammation in Sarcoidosis Patients
and Compare with Healthy People and Heart Attack Patients
Study of Clinical Features and Treatment Results in Adults with Heart Attack and Cardiogenic Shock at Abu Dhabi Hospitals
Evaluating Treatment and Quality Improvement for Adults with Acute ST-Elevation Myocardial Infarction in China
Study of Coronary Thrombus Modification Versus Standard Stent Implantation to Reduce Microvascular Damage in STEMI Patients
Study of Selective C-Reactive Protein Apheresis Using the PentraSorb System in Patients With ST-Elevation Myocardial Infarction Treated With Primary PCI
Study of Dapagliflozin to Reduce Heart Damage in Adults with STEMI Undergoing PPCI
Registry Study on Early Discharge After Heart Attack at Barts Heart Centre
Evaluating Safety and Outcomes for Patients 16 Years and Older with Coronary Artery Disease
Safety and Effectiveness of Half-Dose Recombinant Staphylokinase Before Primary PCI for ST-Elevation Myocardial Infarction A Multicenter Randomized Placebo-Controlled Trial
Study of Umbilical Cord Mesenchymal Stem Cells Added to Standard Treatment for Acute ST-Elevation Myocardial Infarction Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules.